Infectious diseases, along with cancers, are among the main causes of death among
humans worldwide. The production of therapeutic proteins for treating diseases at large …

Antibody‐based cancer therapy, one of the most significant therapeutic strategies, has
achieved considerable success and progress over the past decades. Nevertheless …

With just three CDRs in their variable domains, the antigen-binding site of camelid heavy-
chain-only antibodies (HcAbs) has a more limited structural diversity than that of …

Solubility of recombinant proteins (ie, the extent of soluble versus insoluble expression in
heterogeneous hosts) is the first checkpoint criterion for determining recombinant protein …

The biopharmaceutical market is growing faster than ever, with two production systems
competing for market dominance: mammalian cells and microorganisms. In recent years …

Most nanocarriers possess low drug loading, resulting in frequently repeated administration
and thereby high cost and increased side effects. Furthermore, the characteristics of …

Immunoassays are reliable, efficient, and accurate methods for the analysis of small‐
molecule harmful substances (such as pesticides, veterinary drugs, and biological toxins) …

Monoclonal antibodies (mAbs) are an important class of therapeutic agents approved for the
therapy of many types of malignancies. However, in certain cases applications of …

Protein glycosylation is a very important quality attribute of any biopharmaceutical product
as it affects the efficacy, serum half-life, and antigenicity of a molecule. The present …

A proteolytic strain of Bacillus pumilus MP 27 was isolated from water samples of Southern
ocean produced alkaline protease. Since protease production need expensive ingredients …